Valuation: Nuo Therapeutics, Inc.

Market Cap 62.96M 54.9M 51.84M 47.08M 88.2M 6.04B 88.57M 621M 240M 3.07B 237M 231M 9.88B P/E 2024
-27.4x
P/E 2025 -37.1x
Enterprise Value 63.01M 54.95M 51.88M 47.11M 88.27M 6.05B 88.64M 621M 240M 3.07B 237M 231M 9.89B EV / Sales 2024
47,922,901x
EV / Sales 2025 28,658,774x
Free-Float
42.11%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 63 2016-01-07
Chief Operating Officer 60 2014-03-29
Director TitleAgeSince
Director/Board Member 69 2009-01-29
Chairman 63 2012-02-06
Director/Board Member 67 2016-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-16.66%-.--% - - 62.96M
-0.31%+5.79%+47.13%+99.53% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+5.56%+8.06%+32.49%+30.31% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average -1.36%+1.74%+36.49%+213.13% 30.54B
Weighted average by Cap. +0.19%+1.49%+35.61%+151.94%

Financials

2024 2025
Net sales 1.37 1.19 1.12 1.02 1.91 131 1.92 13.46 5.2 66.6 5.13 5.01 214.29 3.31 2.89 2.73 2.48 4.64 317.95 4.66 32.68 12.61 161.65 12.45 12.17 520.12
Net income -2.32M -2.03M -1.91M -1.74M -3.26M -223M -3.27M -22.92M -8.84M -113M -8.73M -8.54M -365M -2.51M -2.19M -2.07M -1.88M -3.52M -241M -3.53M -24.78M -9.56M -123M -9.44M -9.23M -394M
Net Debt -120K -104K -98.4K -89.35K -167K -11.47M -168K -1.18M -455K -5.83M -449K -439K -18.76M 48.4K 42.2K 39.85K 36.19K 67.8K 4.64M 68.08K 477K 184K 2.36M 182K 178K 7.6M
Logo Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!